Gilgun-Sherki Y[au] - Search Results

Year	Number of Results
2001	1
2002	1
2003	5
2004	3
2005	4
2006	1
2014	2
2015	4
2016	2
2019	1
2021	2
2022	1

1

Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

Boster AL, Ford CC, Neudorfer O, Gilgun-Sherki Y. Boster AL, et al. Among authors: gilgun sherki y. Expert Rev Neurother. 2015 Jun;15(6):575-86. doi: 10.1586/14737175.2015.1040768. Epub 2015 Apr 30. Expert Rev Neurother. 2015. PMID: 25924547 Review.

2

Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.

Tolmasov M, Djaldetti R, Lev N, Gilgun-Sherki Y. Tolmasov M, et al. Among authors: gilgun sherki y. Expert Rev Neurother. 2016 May;16(5):505-13. doi: 10.1586/14737175.2016.1164600. Epub 2016 Mar 25. Expert Rev Neurother. 2016. PMID: 26959397 Review.

3

Therapeutic potential of neurotrophic factors in neurodegenerative diseases.

Levy YS, Gilgun-Sherki Y, Melamed E, Offen D. Levy YS, et al. Among authors: gilgun sherki y. BioDrugs. 2005;19(2):97-127. doi: 10.2165/00063030-200519020-00003. BioDrugs. 2005. PMID: 15807629 Review.

4

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands.

Fleseriu M, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y, Mathias SD. Fleseriu M, et al. Among authors: gilgun sherki y. Front Endocrinol (Lausanne). 2021 Mar 15;12:627711. doi: 10.3389/fendo.2021.627711. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33790860 Free PMC article. Clinical Trial.

5

Antioxidant treatment in Alzheimer's disease: current state.

Gilgun-Sherki Y, Melamed E, Offen D. Gilgun-Sherki Y, et al. J Mol Neurosci. 2003;21(1):1-11. doi: 10.1385/JMN:21:1:1. J Mol Neurosci. 2003. PMID: 14500988 Review.

6

Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.

Gilgun-Sherki Y, Melamed E, Offen D. Gilgun-Sherki Y, et al. Curr Pharm Des. 2006;12(27):3509-19. doi: 10.2174/138161206778343091. Curr Pharm Des. 2006. PMID: 17017944 Review.

7

Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.

Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Gilgun-Sherki Y, et al. Pharmacogenomics J. 2004;4(5):291-306. doi: 10.1038/sj.tpj.6500260. Pharmacogenomics J. 2004. PMID: 15224083 Review.

8

Antioxidant therapy in acute central nervous system injury: current state.

Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Gilgun-Sherki Y, et al. Pharmacol Rev. 2002 Jun;54(2):271-84. doi: 10.1124/pr.54.2.271. Pharmacol Rev. 2002. PMID: 12037143 Review.

9

The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy.

Gilgun-Sherki Y, Melamed E, Offen D. Gilgun-Sherki Y, et al. J Neurol. 2004 Mar;251(3):261-8. doi: 10.1007/s00415-004-0348-9. J Neurol. 2004. PMID: 15015004 Review.

10

Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier.

Gilgun-Sherki Y, Melamed E, Offen D. Gilgun-Sherki Y, et al. Neuropharmacology. 2001 Jun;40(8):959-75. doi: 10.1016/s0028-3908(01)00019-3. Neuropharmacology. 2001. PMID: 11406187 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results